Relevant bibliographies by topics / Drug development Drug design

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Drug development Drug design'

Author: Grafiati
Published: 4 June 2021
Last updated: 16 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Drug development Drug design.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Drug development Drug design"

1

Ranade, Vasant V. "Drug Metabolism in Drug Design and Development." American Journal of Therapeutics 16, no. 5 (2009): 467. http://dx.doi.org/10.1097/mjt.0b013e3181728805.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gupta, Satya Prakash. "Roles of Fluorine in Drug Design and Drug Action." Letters in Drug Design & Discovery 16, no. 10 (2019): 1089–109. http://dx.doi.org/10.2174/1570180816666190130154726.

Full text
Abstract:
The article discusses the basic properties of fluorine atom that have made it so useful in drug development. It presents several examples of therapeutically useful drugs acting against many life-threatening diseases along with the mechanism as to how fluorine influences the drug activity. It has been pointed out that fluorine, due to its ability to increase the lipophilicity of the molecule, greatly affects the hydrophobic interaction between the drug molecule and the receptor. Because of its small size, it hardly produces any steric effect, rather due to electronic properties enters into elec
APA, Harvard, Vancouver, ISO, and other styles
3

Hovgaard, Lars. "Biopharmaceutical Drug Design and Development." Journal of Controlled Release 66, no. 2-3 (2000): 323. http://dx.doi.org/10.1016/s0168-3659(99)00284-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

JOSHI, H. "Drug development and imperfect design☆." International Journal of Pharmaceutics 343, no. 1-2 (2007): 1–3. http://dx.doi.org/10.1016/j.ijpharm.2007.06.046.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Papavassiliou, Athanasios G. "Transcription Factor-Based Drug Design in Anticancer Drug Development." Molecular Medicine 3, no. 12 (1997): 799–810. http://dx.doi.org/10.1007/bf03401717.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

De, Baishakhi, Koushik Bhandari, Francisco J. B. Mendonça, Marcus T. Scotti, and Luciana Scotti. "Computational Studies in Drug Design Against Cancer." Anti-Cancer Agents in Medicinal Chemistry 19, no. 5 (2019): 587–91. http://dx.doi.org/10.2174/1871520618666180911125700.

Full text
Abstract:
Background: The application of in silico tools in the development of anti cancer drugs. Objective: The summing of different computer aided drug design approaches that have been applied in the development of anti cancer drugs. Methods: Structure based, ligand based, hybrid protein-ligand pharmacophore methods, Homology modeling, molecular docking aids in different steps of drug discovery pipeline with considerable saving in time and expenditure. In silico tools also find applications in the domain of cancer drug development. Results: Structure-based pharmacophore modeling aided in the identific
APA, Harvard, Vancouver, ISO, and other styles
7

Olgen, Sureyya. "Overview on Anticancer Drug Design and Development." Current Medicinal Chemistry 25, no. 15 (2018): 1704–19. http://dx.doi.org/10.2174/0929867325666171129215610.

Full text
Abstract:
Background: Many impediments of current anti-cancer therapies have urged scientists to discover new agents. As a result of growing spectrums of new targets and strategies and recent biological and biotechnological progresses, many anti-cancer agents such as monoclonal antibodies, small molecule tyrosine kinase inhibitors and epigenetic drugs have been reached to clinical trials. Objectives: This review helps to understand the rationale for the development of inhibitors against major targets such as cell growth, proliferation, survival, angiogenesis and recent targets such as proteasome, heat s
APA, Harvard, Vancouver, ISO, and other styles
8

Barrawaz, Aateka Y. "COMPUTER AIDED DRUG DESIGN: A MINI-REVIEW." Journal of Medical Pharmaceutical And Allied Sciences 9, no. 5 (2020): 2584–91. http://dx.doi.org/10.22270/jmpas.v9i5.971.

Full text
Abstract:
New drug discovery and development process is considered much complex process which is time consuming and resources accommodating too. So computer aided drug design are being broadly used to enhance the effectiveness of the drug discovery and development process which ultimately saves time and resources. Various approaches to Computer aided drug design are evaluated to shows potential techniques in accordance with their needs. Two approaches are considered to designing of drug first one is structure-based and second one is Ligand based drug designs. In this review, we are discussing about high
APA, Harvard, Vancouver, ISO, and other styles
9

Vilos, Cristian. "Nanotechnology in Preclinical and Clinical Drug Development." International Journal of Medical and Surgical Sciences 1, no. 1 (2018): 73–93. http://dx.doi.org/10.32457/ijmss.2014.011.

Full text
Abstract:
Nanotechnology is generating a strong impact in preclinical and clinical drug development. The diversity of current nanotechnologies offers a broad platform used to enhance the performance of drug discovery screening, to develop sensitive and specific methods used to unveil the mechanisms behind the actions of drugs, to determine the function and interaction between molecules, and to study the physiological and pathological changes of cellular components. In addition, advancements in nanobiotechnology have led to the design of new nanomaterial-based drug candidates that present a novel approac
APA, Harvard, Vancouver, ISO, and other styles
10

Chelamalla, Radhika. "Drug resistance: important criteria for cancer drug development." Pharmaceutical and Biological Evaluations 4, no. 2 (2017): 127. http://dx.doi.org/10.26510/2394-0859.pbe.2017.19.

Full text
Abstract:
Molecularly targeted agents light at end of tunnel to resolve therapeutics by drawing together morbidity and mortality in patients by the whole of cancer. However, still an urgent has a passion for preferably effective anticancer compounds, state-of-the-art preclinical abused substance evaluations largely overlook to answer a need the demand. New preclinical strategies, including the review of with all the extras mouse models and co-clinical design designs, are for used to boost the predictive price tag of animal-based translational aries research. Here, we saw in a new light the society of bo
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Drug development Drug design"

1

Zhang, Huarui. "Design, synthesis and activity evaluation of novel exosome inhibitors." HKBU Institutional Repository, 2020. https://repository.hkbu.edu.hk/etd_oa/849.

Full text
Abstract:
Background: Exosomes are extracellular vesicles (EVs) that produced in the endosomal compartment of most eukaryotic cells, and have observed increasing attentions over the past decades. They play important roles in cell- to-cell communications, they can carry varieties of substances, like proteins, nucleic acids and lipids, to the target cells they encounter. These cargos could influence the function of recipient cells. This novel mode of intercellular communication is found to be of critical importance to many cellular activities. However, exosomes are involved in various diseases processes.
APA, Harvard, Vancouver, ISO, and other styles
2

Chieng, Heng Liang Norman, and n/a. "Amorphous drug preparation using ball milling." University of Otago. School of Pharmacy, 2008. http://adt.otago.ac.nz./public/adt-NZDU20081209.162001.

Full text
Abstract:
Polymorphism and crystallinity are now recognised as important issues in drug development. This is shown by the increased amount of research in this area over recent years. In pharmaceutical development milling is an important unit operation for size reduction to improve powder handling, processing and dissolution rate. The aim of this thesis was to investigate the effect of ball milling (and cryo-milling) on the solid state properties, including amorphous drug formation, of pharmaceutical solids. Milling was carried out using an oscillatory ball mill (Mixer Mill MM301, Retsch GmbH & Co., Ge
APA, Harvard, Vancouver, ISO, and other styles
3

Schreiber, Kimberly C. M. "Assay development for use in drug discovery against Bovine Trichomoniasis." Scholarly Commons, 2007. https://scholarlycommons.pacific.edu/uop_etds/650.

Full text
Abstract:
Bovine trichomoniasis is a venereal disease that affects cattle. The causative agent of this disease is Tritrichomonas foetus, a flagellated protozoan. There is no current FDA approved treatment for this disease. The purpose of this study was to develop new compound screening assays that will make the discovery of new compounds faster and more accurate. The CellTiter-Glo Luminescent Cell Viability Assay, a high throughput screening (HTS) assay from Promega, was found to be as affective at measuring cytotoxicity as traditional assaying techniques. For the first time. preen florescent protein. a
APA, Harvard, Vancouver, ISO, and other styles
4

McCallum, Emma Clare. "Adaptive phase II clinical trial design using nonlinear dose-response models." Thesis, University of Cambridge, 2015. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.709013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Nyberg, Joakim. "Practical Optimal Experimental Design in Drug Development and Drug Treatment using Nonlinear Mixed Effects Models." Doctoral thesis, Uppsala universitet, Institutionen för farmaceutisk biovetenskap, 2011. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-160481.

Full text
Abstract:
The cost of releasing a new drug on the market has increased rapidly in the last decade. The reasons for this increase vary with the drug, but the need to make correct decisions earlier in the drug development process and to maximize the information gained throughout the process is evident. Optimal experimental design (OD) describes the procedure of maximizing relevant information in drug development and drug treatment processes. While various optimization criteria can be considered in OD, the most common is to optimize the unknown model parameters for an upcoming study. To date, OD has mainly
APA, Harvard, Vancouver, ISO, and other styles
6

Valsborg, Jacob Stenmann. "Design and synthesis of radioligands in drug development /." [Cph.] : Royal danish School of Pharmacy, Department of Medicinal Chemistry, 2002. http://www.dfh.dk/phd/defences/jacobvalsborg.htm.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tripathi, Ashutosh. "DEVELOPMENT OF HINT BASED COMPUTATIONAL TOOLS FOR DRUG DESIGN: APPLICATIONS IN THE DESIGN AND DEVELOPMENT OF NOVEL ANTI-CANCER AGENTS." VCU Scholars Compass, 2009. http://scholarscompass.vcu.edu/etd/1866.

Full text
Abstract:
The overall aim of the research is to develop a computational platform based on HINT paradigm for manipulating, predicting and analyzing biomacromolecular-ligand structure. A second synergistic goal is to apply the above methodology to design novel and potent anti-cancer agents. The crucial role of the microtubule in cell division has identified tubulin as an interesting target for the development of therapeutics for cancer. Pyrrole-containing molecules derived from nature have proven to be particularly useful as lead compounds for drug development. We have designed and developed a series o
APA, Harvard, Vancouver, ISO, and other styles
8

Dube, Admire. "The design, preparation and evaluation of Artemisia Afra and placebos in tea bag dosage form suitable for use in clinical trials." Thesis, University of the Western Cape, 2006. http://etd.uwc.ac.za/index.php?module=etd&action=viewtitle&id=gen8Srv25Nme4_2915_1188480959.

Full text
Abstract:
<p>Artemisia Afra, a popular South African traditional herbal medicine is commonly administered as a tea infusion of the leaves. However, clinical trials proving it safety and efficacy are lacking mainly due to the absence of good quality dosage forms and credible placebos for the plant. The objectives of this study were to prepare a standardized preparation of the plant leaves and freeze-dried aqueous extract powder of the leaves, in a tea bag dosage form and to design and prepare credible placebos for these plant materials.</p>
APA, Harvard, Vancouver, ISO, and other styles
9

Cong, Ze. "Value of pharmaceutical innovation the access effects, diffusion process, and health effects of new drugs /." Santa Monica: RAND, 2009. http://www.rand.org/pubs/rgs_dissertations/2009/RAND_RGSD242.pdf.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Zonta, Nicola. "Development and application of modelling techniques in drug design." Thesis, Cardiff University, 2009. http://orca.cf.ac.uk/55854/.

Full text
Abstract:
Structure-based drug design is a creative process that displays several features that make it closer to human reasoning than to machine automation. However, very often the user intervention is limited to the preparation of the input and analysis of the output of a computer simulation. In some cases, allowing human intervention directly in the process could improve the quality of the results by applying the researcher intuition directly into the simulation. Haptic technology has proven to be a useful method to interact in realtime with a virtual environment, enriching the user's experience and
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Drug development Drug design"

1

Zhang, Donglu, Mingshe Zhu, and W. Griffith Humphreys, eds. Drug Metabolism in Drug Design and Development. John Wiley & Sons, Inc., 2007. http://dx.doi.org/10.1002/9780470191699.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Klesov, A. A. Glycobiology and drug design. Edited by American Chemical Society. Division of Carbohydrate Chemistry. American Chemical Society, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

Wu-Pong, Susanna, and Yongyut Rojanasakul, eds. Biopharmaceutical Drug Design and Development. Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-705-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Wu-Pong, Susanna, and Yon Rojanasakul, eds. Biopharmaceutical Drug Design and Development. Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-532-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Theory of drug development. CRC Press/Taylor & Francis Group, 2014.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Klesov, A. A. Glycobiology and drug design. Edited by American Chemical Society. Division of Carbohydrate Chemistry. American Chemical Society, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Drug discovery and development. 2nd ed. Elsevier, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lee, Chi-Jen. Managing biotechnology in drug development. CRC Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zanders, Edward D. Human drug targets: A compendium for pharmaceutical discovery. John Wiley & Sons, 2016.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
10

Turner, J. Rick. New drug development: Design, methodology, and analysis. J. Wiley & Sons, 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Drug development Drug design"

1

Baldwin, John J. "Drug Design." In Drug Discovery and Development. Humana Press, 1987. http://dx.doi.org/10.1007/978-1-4612-4828-6_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Neville, Kathleen A., Ralph E. Kauffman, and Susan M. Abdel-Rahman. "Development and Clinical Trial Design." In Pediatric Drug Development. John Wiley & Sons Ltd., 2013. http://dx.doi.org/10.1002/9781118312087.ch24.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Kompella, Udaya B. "Protein Drug Delivery." In Biopharmaceutical Drug Design and Development. Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-705-5_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Lanfear, Denny, Randy Hassler, Karen Sitney, et al. "Protein Drug Manufacturing." In Biopharmaceutical Drug Design and Development. Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-705-5_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Azad, Neelam, and Yon Rojanasakul. "Macromolecular Drug Delivery." In Biopharmaceutical Drug Design and Development. Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-532-9_14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Bharatam, Prasad V. "Computer-Aided Drug Design." In Drug Discovery and Development. Springer Singapore, 2021. http://dx.doi.org/10.1007/978-981-15-5534-3_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Robins, Roland K., and Ganapathi R. Revankar. "Design of Nucleoside Analogs as Potential Antiviral Agents." In Antiviral Drug Development. Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-7275-2_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Roberts, Stanley M. "Design of Anti-Viral Agents Other than Nucleoside Analogues." In Antiviral Drug Development. Springer US, 1988. http://dx.doi.org/10.1007/978-1-4684-7275-2_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

De Schaepdrijver, Luc M., Graham P. Bailey, Timothy P. Coogan, and Jennifer L. Ingram-Ross. "Juvenile Animal Toxicity Assessments: Decision Strategies and Study Design." In Pediatric Drug Development. John Wiley & Sons Ltd., 2013. http://dx.doi.org/10.1002/9781118312087.ch19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Erhardt, Paul W. "Using Drug Metabolism Databases during Drug Design and Development." In Drug Discovery and Development. John Wiley & Sons, Inc., 2006. http://dx.doi.org/10.1002/0471780103.ch9.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Drug development Drug design"

1

Lee, Jae-Hwan, and Ramana M. Pidaparti. "An Implantable Device Design Concept for Ocular Drug Delivery." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80176.

Full text
Abstract:
New drugs for curing eye diseases have been developing for a decade and are very unique for each eye diseases such as glaucoma, cataracts, and age-related macular degeneration (AMD). It is estimated that 1.6 million adults in the US over the age of 50 and above suffer from age-related macular degeneration and about 200,000 cases are diagnosed annually. Worldwide, about 500,000 cases are diagnosed annually [1]. Drugs currently utilized for AMD are delivered via repeated intravitreal injections of the drug into the eye. Risks of repeated intravitreal injections can include intraocular infections
APA, Harvard, Vancouver, ISO, and other styles
2

Bose, Mausumi Bose. "CROSSOVER DESIGNS FOR DRUG DEVELOPMENT." In 41st International Academic Conference, Venice. International Institute of Social and Economic Sciences, 2018. http://dx.doi.org/10.20472/iac.2018.041.009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sarker, Sunandita, Yiannis S. Chatzizisis, Srivatsan Kidambi, and Benjamin S. Terry. "Design and Development of a Novel Drug Delivery Catheter for Atherosclerosis." In 2018 Design of Medical Devices Conference. American Society of Mechanical Engineers, 2018. http://dx.doi.org/10.1115/dmd2018-6869.

Full text
Abstract:
Atherosclerosis is a chronic progressive cardiovascular disease that results from plaque formation in the arteries. It is one of the leading causes of death and loss of healthy life in modern world. Atherosclerosis lesions consist of sub-endothelial accumulations of cholesterol and inflammatory cells [1]. However, not all lesions progress to the final stage to cause catastrophic ischemic cardiovascular events [2]. Early identification and treatment of high-risk plaques before they rupture, and precipitate adverse events constitutes a major challenge in cardiology today. Numerous investigations
APA, Harvard, Vancouver, ISO, and other styles
4

Wichard, Joerg D., Maciej J. Ogorzalek, and Christian Merkwirth. "CNN in drug design — Recent developments." In 2015 IEEE International Symposium on Circuits and Systems (ISCAS). IEEE, 2015. http://dx.doi.org/10.1109/iscas.2015.7168656.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Blanco, Letia, Panos S. Shiakolas, Pranesh B. Aswath, et al. "A Thermoresponsive Hydrogel Based Controlled Drug Delivery Device." In ASME 2012 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/imece2012-88564.

Full text
Abstract:
Thermoresponsive hydrogels exhibit the unique property of volume change as a function of change in temperature as they transition between hydrophilic and hydrophobic states. These hydrogels can be loaded with drug/protein and serve as reservoirs for drug/protein delivery applications. A hydrogel based device for controlled drug delivery is designed with a number of subsystems that are interfaced with LabVIEW for development of a functional device. The device was designed using analytical and finite element analysis procedures and fabricated. In this manuscript, the device design will be review
APA, Harvard, Vancouver, ISO, and other styles
6

Hossain, A. T. M. Mosharof, Nazia Hasan Tuktuki, Hasibul Kabir, and Rajesh Palit. "Design and Development of a Mobile Application Based Drug Requisition System." In 2016 IEEE International Conference on Computer and Information Technology (CIT). IEEE, 2016. http://dx.doi.org/10.1109/cit.2016.113.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Jawad, Huda M., Ahlam Majead Kadhim, Shaimaa H. Abd Muslim, and Waseem M. Al Juboori. "Design Carbon Nanotubes Drug Delivery to Transport Adrenaline Medication." In 2019 12th International Conference on Developments in eSystems Engineering (DeSE). IEEE, 2019. http://dx.doi.org/10.1109/dese.2019.00133.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Mendes, Pedro J., Joa˜o M. M. Sousa, and Joa˜o F. Pinto. "A Virtual Apparatus for Design and Testing of New Drug Formulations and Devices for Inhalation Therapy." In ASME 2007 2nd Frontiers in Biomedical Devices Conference. ASMEDC, 2007. http://dx.doi.org/10.1115/biomed2007-38027.

Full text
Abstract:
Delivery of drugs to the lungs as aerosols is regarded as an excellent route for local or systemic administration of drugs. Aerosols have been used traditionally for treating illnesses of the respiratory tract (e.g. asthma), but new perspectives and needs on inhalation therapy have recently emerged (e.g. insulin). The percentage of drug that reaches the targeted region, the so-called respirable fraction (RF), is in average only 30% of the dose provided to the patient. Thus, the development of more efficient formulations and devices remains an important issue.
APA, Harvard, Vancouver, ISO, and other styles
9

Tsai, H. R., B. Z. Bentz, V. Chelvam, V. Gaind, K. J. Webb, and P. S. Low. "In Vivo Optical Imaging of Kinetics in a Small Animal for Folate-Targeted Drug Development." In Bio-Optics: Design and Application. OSA, 2013. http://dx.doi.org/10.1364/boda.2013.jw3b.5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Marshall, Lauren, Isabel Löwstedt, Paul Gatenholm, and Joel Berry. "Prevascularized, Co-Culture Model for Breast Cancer Drug Development." In ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80409.

Full text
Abstract:
The objective of this study was to create 3D engineered tissue models to accelerate identification of safe and efficacious breast cancer drug therapies. It is expected that this platform will dramatically reduce the time and costs associated with development and regulatory approval of anti-cancer therapies, currently a multi-billion dollar endeavor [1]. Existing two-dimensional (2D) in vitro and in vivo animal studies required for identification of effective cancer therapies account for much of the high costs of anti-cancer medications and health insurance premiums borne by patients, many of w
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Drug development Drug design"

1

Basu, Sayani. Pharmacognosy in Drug Development. Spring Library, 2021. http://dx.doi.org/10.47496/nl.blog.23.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Anderson, Burt, Richard Heller, Ed Turos, and Mark Mclaughlin. Drug Discovery, Design and Delivery. Defense Technical Information Center, 2012. http://dx.doi.org/10.21236/ada563482.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Novotny, Jaroslav F. Preparation of Bulk Drug for the U.S. Army Drug Development Program. Defense Technical Information Center, 2004. http://dx.doi.org/10.21236/ada425622.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Novotny, Jaroslav. Preparation of Bulk Drug for the U.S. Army Drug Development Program. Defense Technical Information Center, 2001. http://dx.doi.org/10.21236/ada392524.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Seol, Dai-Wu. TRAIL-Based Anticancer Drug Development. Defense Technical Information Center, 2002. http://dx.doi.org/10.21236/ada407205.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Tignor, Gregory H. Drug Development against Viral Diseases. Defense Technical Information Center, 1987. http://dx.doi.org/10.21236/ada201949.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Krieger, Joshua, Danielle Li, and Dimitris Papanikolaou. Missing Novelty in Drug Development. National Bureau of Economic Research, 2018. http://dx.doi.org/10.3386/w24595.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Novotny, Jaroslav F. Preparation of Chemicals and Bulk Drug Substances for the U.S. Army Drug Development Program. Defense Technical Information Center, 1997. http://dx.doi.org/10.21236/adb232976.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Novotny, Jaroslav. Preparation of Chemicals and Bulk Drug Substance for the U.S. Army Drug Development Program. Defense Technical Information Center, 2000. http://dx.doi.org/10.21236/ada382468.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Gaynor, Martin, Jian Li, and William Vogt. Is Drug Coverage a Free Lunch? Cross-Price Elasticities and the Design of Prescription Drug Benefits. National Bureau of Economic Research, 2006. http://dx.doi.org/10.3386/w12758.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Drug development Drug design' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography